The 63rd Sesssion of the Commission on Narcotic Drugs takes place from 2nd to 6th March 2020. TNI and its partners will participate at this annual series of meetings and co-hosts five side events on 5th and 6th March 2020.
Societies in the Americas have coexisted with smokable cocaines for over four decades, but - surprisingly - there is a dearth of research on the development of the market, or much first-hand evidence of how this substance is actually commercialized and used by millions of people in the region. After a few years of field research, our study on the topic will be launched at the Commission on Narcotic Drugs.
As a growing number of countries move towards legal regulation for non-medical cannabis, governments are pushing the boundaries of the three UN drug control treaties. At the 61st session of the Commission on Narcotic Drugs (CND), TNI will co-organise a side event to explore the issue, addressing the various challenges and opportunities involved.
The Transnational Institute (TNI) attended the 59th session of the UN Commission on Narcotic Drugs in Vienna from the 14-22nd March. The CND negotiated the outcome document to be approved at the 2016 UNGASS on the world drug problem, to be held on April 19-21 in New York.
The Transnational Institute (TNI) attends the 59th session of the UN Commission on Narcotic Drugs in Vienna from the 14-22nd March. This storify features tweets, blogs and news from the event. Our team in Vienna includes Martin Jelsma, Pien Metaal and Tom Blickman.
Drug policy experts and impacted communities from around the world express serious concerns about the preparations and already-drafted outcomes for the UN General Assembly Special Session (UNGASS) on the “world drug problem”.
The international drug control regime is facing the most profound challenge of its existence. Member states have for some time been experimenting with new responses to the ‘world drug problem’; however, the advent of legally regulated cannabis markets has resulted in a ratcheting up of these challenges to expose the system to new levels of strain. With the 2016 UN General Assembly Special Session (UNGASS) on the world drug problem fast approaching, how will the international community make use of the opportunity it provides for a free and open debate?
This March, our video advocacy team attended the 58th session of the Commission on Narcotic Drugs, the largest drug policy gathering in the world, to find out how governments and NGOs feel about the prospects of drug policy reform. We produced a series of short thematic videos, to give you an overview of the current state of political debate on the burning issues of international drug control.
With the 2016 UNGASS on drugs in one year, it is time to recognize the policy landscape is shifting while tensions within the UN drug control system continue to grow. A slowly increasing number of governments is expressing their frustrations with the current international drug control framework, particularly Mexico and Colombia, countries that are suffering from violence related to drug markets, are calling for reflection and analysis in order to consider new options, some of which include regulatory measures.
Just over one year away from the 2016 UNGASS, denying the reality that the drug policy landscape has fundamentally changed and that tensions with the UN drug conventions are occuring, is no longer a credible option. Secretary General Ban Ki-moon urged member states to use the 2016 UNGASS on drugs "to conduct a wide-ranging and open debate that considers all options." TNI calls for a special advisory group that should be tasked with recommending how to better deal with the contentious issues following the 2016 UNGASS, in preparation for the next UN high-level review in 2019.
The Commission on Narcotic Drugs (CND) in Vienna will decide next week between two opposite proposals by China and the WHO about international control of ketamine, an essential anaesthetic in human and veterinary medicine. China originally proposed bringing ketamine under the 1971 Convention’s most severe control regime of Schedule I, which would dramatically affect its availability for surgery in poor rural settings and emergency situations. The WHO Expert Committee reviewed all the evidence and advised against any international control of ketamine, arguing it would trigger a public health disaster.
The UN Commission considers to bring ketamine under the control of the 1971 Convention on Psychotropic Substances contrary to WHO recommendations. The 58th Session of the UN Commission on Narcotic Drugs (CND) in March 2015 has been asked to consider a Chinese proposal to place ketamine – an essential medicine used for anaesthesia – in Schedule I of the 1971 Convention (E/CN.7/2015/7 and E/CN.7/2015/81). Ketamine is the only available anaesthetic for essential surgery in most rural areas of developing countries, home to more than 2 billion of the world’s people. Scheduling ketamine under any of the 1971 treaty schedules will reduce its availability and further deepen the already acute crisis of global surgery.
Ketamine is an essential medicine used for anaesthesia. It is the only available anaesthetic for essential surgery in most rural areas of developing countries, home to more than 2 billion of the world’s people. Scheduling ketamine will leave these populations with no alternative anaesthesia for essential surgery, and will further deepen the already acute crisis of global surgery.
The most important drug policy event this quarter was undoubtedly the 57th Session of the UN Commission on Narcotic Drugs (CND) in Vienna from 13 to 21 March, the first two days of which were dedicated to a high-level review of the past five years. The winds of drug policy change were clearly felt in the statements made by several Latin American countries – Colombia, Guatemala, Ecuador, Mexico and Uruguay – and some European countries – the Czech Republic, Norway and Switzerland, among others.
The current trend towards legal regulation of the cannabis market has become irreversible and requires an urgent dialogue by UN member states on the best models for protecting people’s health and safety, argues a new report. The question facing the international community today is no longer whether there is a need to revise the UN drug control system, but rather when and how to do it.
UN’s International Narcotics Control Board (INCB) unprecedented condemnation of the use of death penalty for drug-related offences is welcome if long overdue. The bigger question is whether INCB’s consideration of human rights can be extended into a proper human rights and evidence-based examination of UN’s entire drug control regime.
In March 2014, country delegations will gather at the United Nations Commission on Narcotic Drugs (CND) to review progress and challenges in international drug control since the agreement of a Political Declaration on drugs in 2009. Given that the Political Declaration aims to “eliminate or reduce significantly” the use, supply and demand of controlled drugs by 2019, this meeting represents an important opportunity for honest evaluation and an acknowledgement that these targets are not being achieved. With a United Nations General Assembly Special Session (UNGASS) on drugs just two years away, this is an important time for international drug control policy.